Afrit Mehdi, Yahyaoui Yosra, Bouzouita Aderrazek, Hantous Saoussen, Labidi Soumaya, Chebil Mohamed, Ben Miled Khaoula, Escudier Bernard, Boussen Hamouda
Hôpital Abderrahmane Mami, service d'oncologie médicale, 1005 Tunis, Tunisie.
Hôpital Abderrahmane Mami, service d'oncologie médicale, 1005 Tunis, Tunisie.
Presse Med. 2015 Feb;44(2):135-43. doi: 10.1016/j.lpm.2014.07.020. Epub 2014 Dec 18.
To analyze the medical literature concerning the results of the international randomized muticentric trials concerning therapeutic innovations, mainly targeted therapies in locally advanced and or metastatic renal cell cancer and to evaluate the benefit of these TT.
We performed a review of publications that concerned this topic published from 2000 to 2014.
They concerned the large randomized trials have showed a benefit of the targeted therapies in the treatment of clear cell carcinomas in terms of progression-free survival.
Advances in molecular biology have allowed the development of these targeted therapies that have all proved their role in the treatment of metastatic renal cell carcinoma.
分析关于治疗创新（主要是局部晚期和/或转移性肾细胞癌的靶向治疗）的国际随机多中心试验结果的医学文献，并评估这些靶向治疗的益处。
我们对2000年至2014年发表的有关该主题的出版物进行了综述。
大型随机试验表明，靶向治疗在透明细胞癌的治疗中对无进展生存期有益。
分子生物学的进展使得这些靶向治疗得以发展，它们均已证明在转移性肾细胞癌的治疗中发挥了作用。
